Adial Pharmaceuticals, Inc. (ADIL) |
| 1.58 0.01 (0.64%) 04-14 16:00 |
| Open: | 1.59 |
| High: | 1.635 |
| Low: | 1.57 |
| Volume: | 57,781 |
| Market Cap: | 2(M) |
| PE Ratio: | -0.13 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 2.08 |
| Resistance 1: | 1.87 |
| Pivot price: | 1.67 |
| Support 1: | 1.54 |
| Support 2: | 1.28 |
| 52w High: | 30.25 |
| 52w Low: | 1.54 |
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Financials
| EPS | -11.930 |
| Book Value | 4.750 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -83.2 |
| Return on Equity (ttm) | -170.7 |
Company news
Sun, 12 Apr 2026
ADIL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Thu, 09 Apr 2026
[Form 4] ADIAL PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Thu, 09 Apr 2026
Adial Pharmaceuticals (ADIL) director receives 9,185 stock options at $1.64 strike - Stock Titan
Thu, 09 Apr 2026
Director at Adial (NASDAQ: ADIL) receives 9,185 restricted shares - Stock Titan
Thu, 09 Apr 2026
Adial Pharmaceuticals (NASDAQ: ADIL) CEO granted 37,985 shares - Stock Titan
Tue, 24 Mar 2026
Adial Pharmaceuticals Commends Congress on Introduction of - GlobeNewswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
